House advances multiple bills limiting public funding for gender-related care and tightening rules on minors' treatment

Utah House of Representatives · February 5, 2026

Get AI-powered insights, summaries, and transcripts

Sign Up Free
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

On Feb. 5 the House passed HB174 (making the moratorium on certain gender-related treatments for minors permanent), HB193 (limiting publicly funded insurance coverage of transition procedures), and HB258 (insurance coverage amendments including parity language); votes were 54-15 (HB174), 48-21 (HB193), and 53-16 (HB258).

The Utah House spent a lengthy portion of its Feb. 5 floor session debating a set of bills addressing gender-related medical care and insurance coverage. Lawmakers passed HB174, HB193 and HB258 in separate votes after extended debate that included scientific challenges, ethical arguments and substitute proposals.

Representative Shipp presented HB174 to make permanent the moratorium on puberty blockers, cross-sex hormones and certain surgical procedures for minors and to require discontinuation of grandfathered hormone treatments by Jan. 28, 2027. Shipp characterized the bill as protecting youth and asserted concerns about long-term physical and cognitive effects. Representative Daley-Provost offered a sustained scientific rebuttal, arguing that the transcript of studies and systematic reviews was being selectively cited and that denying care can impose harms; he urged a no vote. After previous-question motions and summation, HB174 passed 54-15.

Representative Peck introduced HB193 to prohibit publicly funded insurance from paying for transition procedures and to require coverage parity for detransition procedures if an insurer previously paid for a transition procedure. Representative Ward offered a substitute splitting hormonal and surgical treatments; Ward argued hormones generally do not drive the fiscal note and separating them prevents downstream access problems for other patients who use the same medicines for non-transition reasons. Peck rejected the substitute as unnecessary and framed the bill as about who pays. The House ultimately passed the original first substitute 48-21.

Representative Peck also presented HB258 (insurance coverage amendments) and accepted a first substitute from Representative Ward to align coverage language; Representative Shelley successfully moved an amendment removing phrasing that a health benefit plan "considers medically necessary," clarifying the elective nature of the procedures in question. The first substitute passed and final passage of HB258 was recorded at 53-16.

Floor debate featured repeated appeals to medical literature, concerns about standards of evidence, questions about fiscal impact, and procedural motions to close debate. Sponsors characterized the measures as preserving public dollars and protecting minors; opponents emphasized adult autonomy, clinical judgment, and potential harms from denying care. Each bill will be transmitted to the Senate for consideration.